Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Prepaid Assets: 2016-2025

Historic Prepaid Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $53.2 million.

  • Ultragenyx Pharmaceutical's Prepaid Assets rose 28.65% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 28.65%. This contributed to the annual value of $40.3 million for FY2024, which is 15.39% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Prepaid Assets is $53.2 million, which was down 13.11% from $61.2 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Prepaid Assets' 5-year high stood at $77.5 million during Q2 2022, with a 5-year trough of $40.3 million in Q4 2024.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Prepaid Assets value was $51.4 million (recorded in 2023), while the average stood at $51.9 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Prepaid Assets crashed by 35.15% in 2023, and later grew by 28.65% in 2025.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Prepaid Assets stood at $71.7 million in 2021, then dropped by 3.93% to $68.9 million in 2022, then tumbled by 30.92% to $47.6 million in 2023, then decreased by 15.39% to $40.3 million in 2024, then climbed by 28.65% to $53.2 million in 2025.
  • Its last three reported values are $53.2 million in Q3 2025, $61.2 million for Q2 2025, and $59.8 million during Q1 2025.